CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company based in China, has announced that it will continue the Phase 2 trial of CAN008 in patients with glioblastoma multiforme (GBM) in China. This decision is based on the interim analysis recommendation of the independent data monitoring committee.
The ongoing Phase 2 study aims to evaluate the efficacy and safety of CAN008 in newly diagnosed GBM patients. Glioblastoma is a challenging cancer with poor patient outcomes under standard-of-care treatments. CAN008 has shown promise as a potentially new treatment option for these patients.
The Phase 2 trial enrolled 119 subjects who were randomized to receive either intravenous CAN008 or placebo, in addition to standard-of-care chemoradiotherapy. The primary endpoint of the study is progression-free survival, while overall survival is a secondary endpoint.
CAN008 is a CD95-Fc fusion protein that blocks the interaction between the CD95 ligand and receptor, inhibiting tumor cell growth and migration and enhancing immune recognition of